Prosecution Insights
Last updated: November 04, 2026

Onyx Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Onyx Therapeutics Inc. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio is engaged in 1 pending office action, reflecting a precise and limited scope of active prosecution. This matter is being reviewed by 1 distinct examiner, which centralizes the company's current interactions with the patent office. The portfolio's activity is also restricted to 1 distinct art unit, indicating that the company's technological focus is currently concentrated in a single specialized area of pharmaceutical technology.

The busiest examiner for Onyx Therapeutics Inc. is MYERS, CARLA J, who is handling the 1 pending office action. As the sole examiner with an active case, MYERS, CARLA J is the primary gatekeeper for the company's current intellectual property goals. For a practitioner, having 1 busiest examiner pending case allows for a deep focus on a single set of examiner concerns rather than managing multiple conflicting requirements. The limitation to 1 distinct art unit further suggests that the prosecution will follow the specific procedural norms of that unit, providing a predictable environment for the company's legal strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MYERS, CARLA J 1 49.5% +46.0%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17903700 IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE MYERS, CARLA J —

Top Art Units

Art UnitApps
1682 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17903700 IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE MYERS, CARLA J 1682 §103Other Final Rejection — Pending Sep 06, 2022

Managing Onyx Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Onyx Therapeutics Inc. have?

Onyx Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Onyx Therapeutics Inc. applications?

Carla J Myers has the most, with 1 of Onyx Therapeutics Inc.'s pending office actions.

What technology area are Onyx Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month